Multiple myeloma treatment costs in China: obtaining a comparable, staged estimate

A newly diagnosed patient receiving induction and maintenance, a patient preparing for autologous transplant and someone considering CAR-T after relapse are following different pathways. Even with the same named medicine, dose, frequency, duration and supportive care can change expenditure. This guide was checked in September 2026 and explains how to request an itemized RMB estimate from a Chinese hospital. No formal quotation for an individual reader has been verified, so an unsupported price range is not provided.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Describe a specific scope: diagnostic review and treatment planning, the proposed induction phase, transplant with early recovery, or CAR-T preparation through an agreed monitoring milestone. “Complete myeloma treatment” is too ambiguous when care may continue through several phases. The pathways distinguished in the EHA–EMN guideline also create different resource requirements.
Bone-targeted treatment, pain control, preventive medicines and immunoglobulin or other support depend on the patient's risks and regimen. Fractures or unstable bones can add orthopedic procedures, radiation and rehabilitation. The IMWG bone-disease recommendations place these measures within myeloma care, rather than outside the treatment pathway.
Place diagnostic review, medicines, administration and rooms, specific monitoring, support, follow-up and nonmedical expenditure side by side. Mark each item as included, excluded or unresolved. Use the same treatment phase and time horizon, with both hospitals assessing the same records. A quotation assuming no infection or dialysis is not directly comparable with one that includes these needs.

Quick answer

Full guide

Define the clinical endpoint covered by the quotation

Describe a specific scope: diagnostic review and treatment planning, the proposed induction phase, transplant with early recovery, or CAR-T preparation through an agreed monitoring milestone. “Complete myeloma treatment” is too ambiguous when care may continue through several phases. The pathways distinguished in the EHA–EMN guideline also create different resource requirements.

State which tests and treatments have already been completed, whether kidney injury or infection is present, and where subsequent care is intended to occur. An estimate ending at discharge differs from one including later maintenance. Ask for its date, underlying patient information and unresolved assumptions so that it can be updated rather than mistaken for a permanent total.

Determine which diagnostic information the new hospital can use

The initial assessment may involve blood and urine protein studies, marrow examination, pathology review, flow cytometry and genetic testing. Not everyone needs the entire work-up repeated, but an outside report may not answer the new clinical question. The NICE myeloma diagnostic recommendations explain the different purposes of these investigations.

Provide complete reports and information about available slides or specimens. This helps identify what can be reused and what requires confirmation. Mark optional investigations as conditional in the estimate. International patients should also ask whether translation, specimen transfer and pathology consultation carry separate fees; the institution must confirm its actual services.

Link imaging costs to the decision being made

Whole-body low-dose CT, MRI, PET/CT and radiation-planning CT should not be combined under an unspecified “scan” item. They can investigate bone destruction, neural compression, active lesions or treatment geometry. The physician should explain what decision each examination informs and whether recent usable images already answer it. The IMWG imaging recommendations support selecting investigations by purpose.

Separate baseline imaging from later response assessment, and clarify whether contrast, preparation and reporting are included. A patient unable to lie flat or affected by severe bone pain may need additional assistance. Do not assume that every possible scan is required, but do not omit urgent imaging for suspected cord compression solely to preserve an initial budget.

Specify medicines by formulation and time interval

Ask the hospital to list the generic name, formulation, route, planned frequency and estimated number of cycles for each anticancer medicine. Intravenous and subcutaneous formulations, different partners and later frequency changes may affect cost. Clarify whether billing follows the amount used or supplied packaging, and how the estimate changes after dose modification.

Chinese indications must be checked against current product information and updates. The National Health Commission's 2025 anticancer guidance provides a reference, but does not establish hospital stock, international-patient payment eligibility or individual suitability. Overseas authorization should not be treated as proof of routine Chinese supply. Ask separately about availability, insurance conditions and self-pay arrangements.

Include preparation and recovery in a transplant estimate

Autologous transplant involves assessment, mobilization, collection, processing and storage, high-dose conditioning, cell infusion and recovery. Additional collection or mobilization, transfusion and infection management can change the actual bill. A single item labeled “transplant fee” does not reveal the scope. The EBMT myeloma chapter explains how these clinical steps fit together.

Request clarification about the room, vascular access, medicines, blood products, tests and post-discharge visits. If cells are collected but transplant is deferred, distinguish storage costs from a later admission. Companion arrangements and accommodation near the center also need confirmation; they should not be assumed to be included merely because a hospital estimate has been issued.

CAR-T and bispecific therapy have different cost structures

CAR-T can involve collection, manufacturing-related charges, bridging therapy during the wait, lymphodepletion, infusion and monitoring. Ask how incurred costs are handled if manufacturing or the patient's condition prevents the planned next step. Comparing a cellular product price with the price of one antibody dose does not establish which entire pathway costs less.

Bispecific therapy does not generally require individualized cell manufacture, but step-up observation, repeated administration and infection care can continue. The bispecific infection-management consensus explains the need for ongoing support. Compare options over the same stated observation period, distinguishing preparation from continuing expenditure. Neither “one infusion” nor “per injection” describes the whole financial burden.

Supportive care may materially affect the budget

Bone-targeted treatment, pain control, preventive medicines and immunoglobulin or other support depend on the patient's risks and regimen. Fractures or unstable bones can add orthopedic procedures, radiation and rehabilitation. The IMWG bone-disease recommendations place these measures within myeloma care, rather than outside the treatment pathway.

Persistent renal injury can require renal consultation, prescription adjustment, electrolyte testing or dialysis. The IMWG renal recommendations emphasize individualized management. Separate support already known to be necessary from contingent expenditure. A transparent estimate should neither assume every possible complication will occur nor omit all supportive care to display a misleadingly low total.

Follow the prescription's specific monitoring requirements

Belantamab-containing treatment requires eye monitoring, and corneal or visual problems can lead to further visits and treatment modification. A quotation covering only medicine and administration misses this element. The FDA belantamab combination information supports identifying eye assessment as a relevant item; that US approval does not itself establish Chinese access.

Other regimens may need cardiac, infectious-disease or dental assessment. Once treatment is defined, ask for its required monitoring rather than purchasing a generic comprehensive check-up. If a package excludes a necessary examination, clarify when it is expected, which department arranges it and how it is billed.

Estimate maintenance over explicit periods

Maintenance can be prolonged, while defined-duration treatment may be discussed for appropriate populations. The 2026 ENDURANCE study added evidence on two-year lenalidomide maintenance in selected standard-risk patients not receiving upfront transplant, but it cannot set a universal stopping date. The original trial report must be interpreted in relation to the person's pathway.

Use specified phases or time intervals for financial planning rather than a purported lifetime total. Recalculate medicines, monitoring and travel when treatment changes. Legal medicine supply after return, local prescribing and acceptance of laboratory results can affect continuing costs. Resolve those arrangements before departure rather than after the remaining supply runs out.

Verify insurance and international-patient payment separately

Inclusion of a drug in an insurance list does not establish the same payment for every international patient, indication or hospital. Enrollment, prescribing conditions, institutional supply and settlement procedures may differ. No individual coverage has been verified here, so a hypothetical reimbursement percentage should not be deducted from a self-pay estimate. Ask both the insurer and hospital about preauthorization, direct billing and treatment-specific restrictions.

Confirm the recipient of payment, how deposits are applied, how unused amounts are settled and what itemized invoices are available. Currency conversion should specify the exchange-rate date and payment charges; exchange movements are separate from a fixed RMB service price. Translation or coordination contracts should also identify their own scope so that they can be distinguished from the hospital's clinical bill.

A clinical trial is not automatically an entirely free course

Study medicine, research-only investigations, routine care, complication management and travel or living expenses may have different payers. Read the protocol's financial terms, including screening failure, early withdrawal and access after study treatment ends. The NCI trial-cost explanation helps distinguish categories, but US insurance rules should not be assumed to apply in China.

For an offer described as free CAR-T or an all-inclusive new-drug study, identify the registration number, research hospital and actual coverage. International participation, an open place and personal eligibility require separate confirmation. Paying a coordination fee does not establish trial eligibility. Keep a feasible standard-treatment alternative in the financial plan if screening is unsuccessful.

Compare the same clinical scope

Place diagnostic review, medicines, administration and rooms, specific monitoring, support, follow-up and nonmedical expenditure side by side. Mark each item as included, excluded or unresolved. Use the same treatment phase and time horizon, with both hospitals assessing the same records. A quotation assuming no infection or dialysis is not directly comparable with one that includes these needs.

The useful outcome is a dated written estimate that states its scope and can change with the clinical plan. It should distinguish prescribed expenditure, items awaiting test results and possible additional care. Such an estimate cannot eliminate every uncertainty, but it allows treatment decisions, available funds and continuing care after return to be planned on the same basis.